Scarica l'app Stockscreener
1.46
0.00%
0.00
Dopo l'orario di chiusura:
1.49
0.03
+2.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACRS Giù?
Forum
Previsione
Precedente Chiudi:
$1.46
Aprire:
$1.45
Volume 24 ore:
749.82K
Relative Volume:
0.84
Capitalizzazione di mercato:
$158.09M
Reddito:
$27.08M
Utile/perdita netta:
$-37.00M
Rapporto P/E:
-2.8077
EPS:
-0.52
Flusso di cassa netto:
$-18.46M
1 W Prestazione:
+15.87%
1M Prestazione:
+9.77%
6M Prestazione:
-64.13%
1 anno Prestazione:
+39.05%
Intervallo 1D:
$1.39
$1.475
Intervallo di 1 settimana:
$1.27
$1.56
Portata 52W:
$0.9903
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Nome
Aclaris Therapeutics Inc
Settore
Industria
Telefono
484-324-7933
Indirizzo
701 LEE ROAD, WAYNE, PA
Confronta ACRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.46 | 136.43M | 27.08M | -37.00M | -18.46M | -0.52 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-18 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-11-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-19 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Iniziato | Evercore ISI | Outperform |
| 2022-12-14 | Iniziato | Stifel | Buy |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2022-10-06 | Iniziato | BTIG Research | Buy |
| 2021-07-23 | Ripresa | Jefferies | Buy |
| 2021-06-15 | Iniziato | Piper Sandler | Overweight |
| 2021-04-21 | Iniziato | H.C. Wainwright | Buy |
| 2019-10-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Iniziato | SVB Leerink | Outperform |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2018-02-09 | Iniziato | Guggenheim | Buy |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Iniziato | Leerink Partners | Outperform |
| 2016-09-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-06-10 | Iniziato | Guggenheim | Buy |
| 2015-11-02 | Iniziato | Citigroup | Buy |
| 2015-11-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie
What is Wedbush’s Forecast for ACRS Q2 Earnings? - Defense World
Aclaris Therapeutics to Present at Two Major Healthcare Conferences in June 2025 - MSN
Millennium Management LLC Decreases Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Coverage Initiated by Analysts at Wedbush - Defense World
Aclaris Therapeutics to Participate in Two June Healthcare Conferences - GlobeNewswire
Aclaris Therapeutics Secures Double Speaking Slots at Major June Healthcare Conferences - Stock Titan
Wedbush sets Aclaris stock Outperform with $8 target By Investing.com - Investing.com India
Wedbush Initiates Coverage of Aclaris Therapeutics (ACRS) with Outperform Recommendation - Nasdaq
Aclaris Therapeutics (ACRS) Receives Outperform Rating from Wedbush | ACRS Stock News - GuruFocus
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Aclaris Therapeutics (ACRS) Receives Positive Outlook from Wedbush | ACRS Stock News - GuruFocus
Aclaris Therapeutics (ACRS) Receives Positive Rating from Wedbush | ACRS Stock News - GuruFocus
Wedbush Initiates Aclaris Therapeutics at Outperform With $8 Price Target - marketscreener.com
Costco (COST) Is About to Report Q3 Earnings. Here’s What to Expect - The Globe and Mail
Options Volatility and Implied Earnings Moves Today, May 27, 2025 - The Globe and Mail
Prediction: This Will Be the First Mega Technology Company to Split Its Stock in 2025 (and It Isn't Tesla) - The Globe and Mail
Common Warts Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma Inc - The Globe and Mail
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) PT at $10.00 - Defense World
HC Wainwright Has Positive Forecast for ACRS Q3 Earnings - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Holdings Raised by Dimensional Fund Advisors LP - Defense World
Aclaris Therapeutics to Host Virtual Fireside Chat with CEO Neal Walker on May 16, 2025 - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stake Reduced by Price T Rowe Associates Inc. MD - Defense World
Aclaris Therapeutics (ACRS) Price Target Update by HC Wainwright & Co. | ACRS Stock News - GuruFocus
Aclaris Therapeutics (ACRS) Receives Lower Price Target from Ana - GuruFocus
Aclaris Therapeutics Reports Q1 2025 Financial Results - MSN
Androgenetic alopecia Pipeline 2025: Groundbreaking Clinical - openPR.com
Aclaris Therapeutics Reports Q1 2025 Results and Pipeline Updates - MSN
Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MSN
Scotiabank Has Lowered Expectations for Aclaris Therapeutics (NASDAQ:ACRS) Stock Price - Defense World
Aclaris Therapeutics (ACRS) Price Target Lowered by Scotiabank | - GuruFocus
Aclaris Therapeutics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Raymond James Financial Inc. Purchases New Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series - GlobeNewswire
Scotiabank Adjusts Price Target for Aclaris Therapeutics (ACRS) - GuruFocus
Aclaris Therapeutics to Participate in the HC Wainwright 'HCW@Home” Series - The Manila Times
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series - GlobeNewswire Inc.
Mariner LLC Sells 10,327 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Aclaris: Q1 Earnings Snapshot - CT Insider
Aclaris Therapeutics Inc earnings beat by $0.02, revenue fell short of estimates - Investing.com India
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Aclaris Therapeutics Reports Q1 2025 Financial Results and Corporate Update with Focus on Immuno-Inflammatory Developments and Extended Cash Runway through 2028 - Nasdaq
Aclaris Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Hims & Hers Has a Superpower in Healthcare - The Globe and Mail
Here's Why I'm Still Buying SoFi Hand Over Fist in 2025 - The Globe and Mail
Aclaris Therapeutics Inc (ACRS)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - DWinneX
Invesco Ltd. Invests $28,000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Acquired by JPMorgan Chase & Co. - Defense World
Aclaris Therapeutics Inc Azioni (ACRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):